What type of study is this?

This is a Pre-Registered Trial study.

October 23, 2025Future Oncology

ASTRON (OGSG 2401) study protocol: Ferric carboxymaltose for iron deficiency anemia in gastrointestinal cancer

View Full Paper

Ask AI

Bookmark

Authors

HYHiroki YukamiOsaka University of Pharmaceutical Sciences TYToshifumi YamaguchiOsaka Medical and Pharmaceutical University SEShunji EndoKawasaki Medical School

Discussion

Member takes

Implication

Protocol examines ferric carboxymaltose's effectiveness in improving quality of life for anemia in chemotherapy patients, suggesting new treatment pathways.

Key Points

Improved quality of life associated with treatment for iron deficiency anemia in gastrointestinal cancer patients.
Study focuses on iron deficiency anemia during chemotherapy, a major issue for patient well-being.
Trial evaluates ferric carboxymaltose against limitations of current treatments for anemia, including transfusions.
Findings may highlight new treatment options for managing anemia in patients with gastrointestinal cancer.”

Cite This Study

Yukami et al. (2025) studied this question.

synapsesocial.com/papers/68f9d6583f378872224924fd https://doi.org/10.1080/14796694.2025.2569574

View Full Paper

Ask AI

Bookmark

Implication

Protocol examines ferric carboxymaltose's effectiveness in improving quality of life for anemia in chemotherapy patients, suggesting new treatment pathways.

ASTRON (OGSG 2401) study protocol: Ferric carboxymaltose for iron deficiency anemia in gastrointestinal cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

ASTRON (OGSG 2401) study protocol: Ferric carboxymaltose for iron deficiency anemia in gastrointestinal cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider